Verification register Bio, Health & Neuro
Living definition
What is Gedatolisib (Revtorpyk)?
Drug Discovery & Development Bio, Health & Neuro
- As of
- 2026-10-01
- Revision
- 2026-10-06.1
- Method
- v1.4.0
Definition
The term, in context
AI-assisted draft · approved dataset
Gedatolisib (Revtorpyk) is a small-molecule inhibitor targeting the PI3K and mTOR signalling pathway, developed as a treatment for advanced breast cancer.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-10-01, verified readiness is 55 (claimed 55, reported 55, gap 0) — Critical evidence strength; current signals suggest A commercially available U.S. treatment option within its approved breast-cancer indication.
The readiness fact belongs to the canonical Readiness Verdict for Gedatolisib (Revtorpyk).
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06